Rare disease treatment continues to attract growing pharmaceutical investment, and acromegaly, a chronic hormonal disorder caused by excess growth hormone, is no exception. According to a newly released acromegaly treatment market report from Kings Research, the global market was valued at USD 1,787.6 million in 2025 and is expected to grow at a compound annual growth rate of 7.04% to reach USD 3,080.9 million by 2033. The growth is being driven largely by improved diagnostic capability, rising clinical awareness, and a wave of therapeutic innovation that is beginning to shift the treatment paradigm away from frequent injections toward more convenient oral options.
A Rare Disease Gaining Diagnostic Momentum
Acromegaly occurs in an estimated 3 to 14 people per 100,000 worldwide, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Because the condition develops gradually and its symptoms can be subtle in early stages, historical underdiagnosis has long been a challenge. That is beginning to change as clinical awareness improves and diagnostic tools become more sophisticated. High-resolution pituitary MRI imaging and standardized insulin-like growth factor 1 (IGF-1) blood assays are enabling more accurate and timely diagnoses, helping more patients access treatment earlier in the disease’s progression.
Awareness campaigns are reinforcing this trend. In March 2024, Chiesi Global Rare Diseases launched its “Rethink Acromegaly” initiative, aimed at equipping patients, caregivers, and healthcare providers with resources that support earlier diagnosis and better disease management. As these kinds of educational efforts expand, particularly in developing regions where healthcare access is improving, the diagnosed patient population is expected to continue growing, creating a larger addressable market for pharmaceutical companies developing targeted therapies.
Key Market Highlights
The report identifies several notable data points shaping the current market picture. North America held the largest regional share in 2026, at 37.25%, equivalent to USD 712.8 million. Within drug classes, somatostatin analogues (SSAs) accounted for 33.51% of market share in 2026, generating USD 641.2 million in revenue. Hospital pharmacies are projected to be the leading distribution channel, expected to contribute USD 1,150.5 million in revenue by 2033. Meanwhile, Asia-Pacific is anticipated to be the fastest-growing region, posting a CAGR of 7.89% through the forecast period.
The Shift Toward Oral Therapies
Historically, acromegaly management has relied heavily on injectable somatostatin analogues, which require regular deep intramuscular administration and frequent clinic visits. This treatment burden has long been recognized as a barrier to patient adherence, prompting the industry to pursue less invasive alternatives. That shift reached a milestone in September 2025 when the U.S. Food and Drug Administration approved PALSONIFY (paltusotine), developed by Crinetics Pharmaceuticals, as the first once-daily oral somatostatin receptor type 2 agonist approved for adult acromegaly patients. This approval represents a significant departure from the injectable-dominant treatment landscape that has defined the field for decades.
Other companies are following suit with next-generation formulations designed to reduce treatment burden without sacrificing efficacy. In July 2026, the FDA accepted Camurus’s resubmitted New Drug Application for CAM2029, an octreotide subcutaneous depot formulation known as Oczyesa, with a PDUFA target action date of December 18, 2026. Delivered via a prefilled auto-injector, this candidate reflects the broader industry push toward patient-centric delivery mechanisms that reduce the friction associated with chronic disease management.
Managing the Long-Term Treatment Burden
One of the central challenges facing the acromegaly treatment market is the complexity of long-term disease management. Patients typically require ongoing biochemical monitoring, frequent parenteral injections, and periodic dose adjustments, all of which place a considerable burden on both patient adherence and healthcare system workflow. This challenge has become a primary catalyst behind the industry’s push toward once-daily oral therapies, which eliminate the need for frequent depot injections and simplify chronic care administration considerably.
As more oral options move through the pipeline, the market is likely to see continued differentiation between injectable and oral treatment pathways, with patient preference increasingly favoring convenience-driven options that don’t compromise on therapeutic control.
Market Segmentation Breakdown
By drug class, somatostatin analogues remain the market leader, having earned USD 641.2 million in 2026 due to their established role as first-line therapy. Growth hormone receptor antagonists, led by pegvisomant, serve as an important second-line option for patients with incomplete response to SSAs, while dopamine agonists such as cabergoline and bromocriptine provide additional combination therapy support. A growing pipeline of novel oral candidates and nonpeptide SSTR2 agonists is expanding what the report categorizes as the “Others” segment.
In terms of route of administration, injectable products continue to generate the largest share of revenue, driven by widespread use of long-acting depot formulations such as octreotide LAR and lanreotide depot. However, the oral route is rapidly gaining ground following paltusotine’s approval. By distribution channel, hospital pharmacies held a 37.34% share in 2026 and are projected to reach USD 1,150.5 million by 2033, reflecting their central role in dispensing specialized injectable formulations and rare disease therapies more broadly.
Regional Analysis
North America’s market leadership, with a 37.25% share valued at USD 712.8 million in 2026, is rooted in the region’s sophisticated healthcare infrastructure, high disease awareness, and strong adoption of novel therapies. The presence of leading pharmaceutical innovators, robust R&D investment, and favorable reimbursement coverage all support high rates of both diagnosis and treatment across the region.
Asia-Pacific, projected to grow at a CAGR of 7.89% through 2033, is being propelled by expanding healthcare infrastructure, rising awareness of rare endocrine conditions, and improving diagnostic capabilities in countries such as China, Japan, and India. Growing healthcare expenditure and an increasing number of specialized endocrine centers across the region are further contributing to this accelerated growth trajectory.
Regulatory Landscape
In the United States, the FDA regulates acromegaly treatments through rigorous clinical trial assessments, pre-market approvals, orphan drug designations, and continuous post-market safety monitoring. In the European Union, the European Medicines Agency oversees acromegaly therapeutics through centralized marketing authorization and strict manufacturing guidelines designed to ensure safety, efficacy, and quality standards are consistently met across member states.
Competitive Landscape
Key players in the acromegaly treatment market include Novartis Pharmaceuticals Corporation, Sun Pharmaceutical Industries Ltd., Chiesi Group, Peptron, Wockhardt, Pfizer Inc., ADVANZ PHARMA, Amryt Pharma plc, Cipla, Ipsen Pharma, Viatris Inc., Zydus Pharmaceuticals, Teva Pharmaceutical Industries, Recordati Rare Diseases, Crinetics Pharmaceuticals, and Xeris Pharmaceuticals. Companies across this competitive set are concentrating development efforts on oral formulations, extended-release injectable depots, and novel receptor agonists that improve both disease control and patient convenience.
Recent developments underscore the pace of innovation in the space. Beyond the PALSONIFY approval and the CAM2029 regulatory submission, Teva Pharmaceutical Industries launched the first generic version of Sandostatin LAR Depot in the U.S. in October 2024, a move that is expanding cost-effective access to established injectable therapies for patients and healthcare systems alike.
Outlook
With diagnostic capabilities improving, awareness campaigns expanding patient identification, and a new generation of oral therapies entering the market, the acromegaly treatment landscape appears set for a period of meaningful transformation through 2033. The interplay between established injectable standards of care and emerging convenience-focused oral options is likely to define competitive dynamics in the years ahead, with hospital pharmacies expected to remain the dominant distribution channel as specialized rare disease therapies continue reaching a broader population of diagnosed patients.